Skip to main content
. Author manuscript; available in PMC: 2020 Oct 15.
Published in final edited form as: Cancer. 2019 Jul 10;125(20):3666–3677. doi: 10.1002/cncr.32370

Table 3.

Emotional outcomes across racial/ethnic groups of childhood cancer survivors.

White, non-Hispanic Black, non-Hispanic Hispanic
Mean P Mean P P* Mean P P*
Depression
Sibling 47.25 47.21 46.02
Survivor 48.33 48.70 49.61
Survivor-sibling difference 1.09 <0.001 1.49 0.23 0.75 3.59 <0.001 0.004
Survivor no CRT 48.16 48.47 49.55
Survivor-sibling difference 0.91 <0.001 1.26 0.33 0.79 3.52 <0.001 0.004
Survivor with CRT 48.82 49.30 49.81
Survivor-sibling difference 1.57 <0.001 2.09 0.23 0.77 3.78 0.003 0.09
Anxiety
Sibling 46.77 44.54 46.16
Survivor 46.86 45.41 47.80
Survivor-sibling difference 0.09 0.68 0.87 0.47 0.52 1.64 0.10 0.13
Survivor no CRT 47.06 45.73 47.83
Survivor-sibling difference 0.29 0.19 1.19 0.35 0.48 1.67 0.11 0.19
Survivor with CRT 46.30 44.58 47.70
Survivor-sibling difference −0.47 0.11 0.04 0.98 0.71 1.54 0.25 0.14
Somatization
Sibling 48.11 47.68 48.92
Survivor 49.14 50.67 50.35
Survivor-sibling difference 1.03 <0.001 3.00 0.01 0.11 1.43 0.12 0.67
Survivor no CRT 49.11 50.37 50.16
Survivor-sibling difference 1.00 <0.001 2.70 0.03 0.18 1.24 0.19 0.80
Survivor with CRT 49.23 51.44 50.95
Survivor-sibling difference 1.12 <0.001 3.76 0.02 0.11 2.03 0.10 0.47
Global severity index
Sibling 46.74 45.08 46.11
Survivor 47.52 47.60 48.95
Survivor-sibling difference 0.78 <0.001 2.52 0.08 0.23 2.85 0.005 0.05
Survivor no CRT 47.48 47.40 48.87
Survivor-sibling difference 0.74 0.002 2.33 0.12 0.30 2.76 0.009 0.06
Survivor with CRT 47.64 48.10 49.23
Survivor-sibling difference 0.90 0.005 3.02 0.10 0.25 3.12 0.04 0.14

P=p-value comparing survivors to same race/ethnicity siblings; P*=p-value comparing survivor-sibling difference between racial/ethnic groups, referenced to non-Hispanic white survivor-sibling difference.

Adjusted for sex, age at follow-up, year at diagnosis, methotrexate exposure (intravenous and intrathecal), corticosteroid exposure and any CTCAE grade 3-4 chronic medical condition.